Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01729286 · ClinicalTrials.gov registry record · NA

Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix

A NA study, sponsored by Integra LifeSciences Corporation.

Terminated
Registry status
NA
Development phase
92
Enrollment target

NCT01729286: Clinical Trial NA study, sponsored by Integra LifeSciences Corporation.

NCT01729286 is a NA study that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 92 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01729286, a NA study, was terminated before completion, sponsored by Integra LifeSciences Corporation.

TERMINATED
Registry status
NA
Development phase
92 participants
Enrollment target

Study Summary

The objective of this study is to compare the effectiveness of PriMatrix Moist Wound Therapy (MWT) with Standard of Care MWT for the treatment of chronic diabetic foot ulcers in subjects with diabetes mellitus and without significantly compromised arterial circulation.

Interventions

  • DEVICE PriMatrix Moist Wound Therapy
  • OTHER Standard of Care Moist Wound Therapy

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2012-09
Est. Completion 2016-10
Phase NA
Integra LifeSciences Corporation

60 total trials

Why NCT01729286 stopped before completion

NCT01729286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which PriMatrix Moist Wound Therapy is the first listed.

NCT01729286 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01729286 about?

NCT01729286 is a clinical study titled "Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix". The objective of this study is to compare the effectiveness of PriMatrix Moist Wound Therapy (MWT) with Standard of Care MWT for the treatment of chronic diabetic foot ulcers in subjects with diabetes mellitus and without significantly compromised arterial circulation.

What is the current status of trial NCT01729286?

This trial is currently terminated. It is a NA study. The enrollment target is 92 participants. The study started on 2012-09. Estimated completion is 2016-10.

What interventions are being tested in trial NCT01729286?

The interventions under investigation include: PriMatrix Moist Wound Therapy (DEVICE), Standard of Care Moist Wound Therapy (OTHER).

Who is sponsoring clinical trial NCT01729286?

This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01729286's enrollment target sits among peer trials

92 937th of 2000 higher than 1,062 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03184545 · 92 participants · Phase 3

    Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome

  • NCT04172532 · 92 participants · Phase 1

    Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  • NCT04508088 · 92 participants

    Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

  • NCT04840602 · 92 participants · Phase 2

    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01729286, the US trial registry maintained by the National Library of Medicine. NCT01729286 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.